Banks ML, Blough BE, Stevens Negus S (2013) Interaction between behavioral and pharmacological treatment strategies to decrease cocaine choice in rhesus monkeys. Neuropsychopharmacology 38:395–404
Banks ML, Bauer CT, Blough BE, Rothman RB, Partilla JS, Baumann MH, Negus SS (2014) Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys. Exp Clin Psychopharmacol 22:274–284
Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB (2011) In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337:218–225
Baumann MH, Partilla JS, Lehner KR (2013) Psychoactive “bath salts”: not so soothing. Eur J Pharmacol 698:1–5
Blough B (2008) Dopamine releasing agents. In: Trudell M (ed) Dopamine transporters: chemistry, biology, and pharmacology (a Wiley series in drug discovery and development). Wiley, Hoboken
Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, Rothman RB (2014a) Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. ACS Med Chem Lett 5:623–627
Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB (2014b) Alpha-ethyltryptamines as dual dopamine-serotonin releasers. Bioorg Med Chem Lett 24:4754–4758
Bonano JS, Banks ML, Kolanos R, Sakloth F, Barnier ML, Glennon RA, Cozzi NV, Partilla JS, Baumann MH, Negus SS (2015) Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharmacol 172:2433–2444
Botanas CJ, Yoon SS, de la Pena JB, Dela Pena IJ, Kim M, Woo T, Seo JW, Jang CG, Park KT, Lee YH, Lee YS, Kim HJ, Cheong JH (2017) A novel synthetic cathinone, 2-(methylamino)-1-(naphthalen-2-yl) propan-1-one (BMAPN), produced rewarding effects and altered striatal dopamine-related gene expression in mice. Behav Brain Res 317:494–501
Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, Decker AM, Landavazo A, McElroy KT, Navarro HA, Gatch MB, Forster MJ (2009) Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem 52:6768–6781
Carroll FI, Blough BE, Mascarella SW, Navarro HA, Eaton JB, Lukas RJ, Damaj MI (2010) Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem 53:2204–2214
Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014) Bupropion and bupropion analogs as treatments for CNS disorders. Adv Pharmacol 69:177–216
Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180–187
Del Bello F, Sakloth F, Partilla JS, Baumann MH, Glennon RA (2015) Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: interactions with transporters for serotonin, dopamine, and norepinephrine. Bioorg Med Chem 23:5574–5579
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A (2017) Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release. J Pharmacol Exp Ther 360:33–47
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol 47:681–698
Foley KF, Cozzi N (2003) Novel aminopropiophenones as potential antidepressants. Drug Dev Res 60:252–260
Gatch MB, Rutledge MA, Forster MJ (2015) Discriminative and locomotor effects of five synthetic cathinones in rats and mice. Psychopharmacology 232:1197–1205
Glennon RA, Dukat M (2017) Structure-activity relationships of synthetic cathinones. Curr Top Behav Neurosci 32:19–47
Glennon RA, Yousif M, Naiman N, Kalix P (1987) Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 26:547–551
Gregg RA, Baumann MH, Partilla JS, Bonano JS, Vouga A, Tallarida CS, Velvadapu V, Smith GR, Peet MM, Reitz AB, Negus SS, Rawls SM (2015) Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br J Pharmacol 172:883–894
Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, Negus SS (2016) Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. Eur Neuropsychopharmacol 26:288–297
Hyde JF, Browning E, Adams R (1928) Synthetic homologs of d,l-ephedrine. J Am Chem Soc 50:2287–2292
Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther 90:246–255
Kaminski BJ, Griffiths RR (1994) Intravenous self-injection of methcathinone in the baboon. Pharmacol Biochem Behav 47:981–983
Kohut SJ, Jacobs DS, Rothman RB, Partilla JS, Bergman J, Blough BE (2017) Cocaine-like discriminative stimulus effects of “norepinephrine-preferring” monoamine releasers: time course and interaction studies in rhesus monkeys. Psychopharmacology 234:3455–3465
L’Italien YJ, Park H, Rebstock MC (1957) Methylaminopropiophenone compounds and methods for producing the same. In: Office USP (ed) United States Patent Office. Parke, Davis and Company, US, pp 3
Li M, Farley RA, Lester HA (2002) Voltage-dependent transient currents of human and rat 5-HT transporters (SERT) are blocked by HEPES and ion channel ligands. FEBS Lett 513:247–252
Luethi D, Kolaczynska KE, Docci L, Krahenbuhl S, Hoener MC, Liechti ME (2018) Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology 134:4–12
Masson J, Sagne C, Hamon M, El Mestikawy S (1999) Neurotransmitter transporters in the central nervous system. Pharmacol Rev 51:439–464
Partilla JS, Baumann MH, Decker AM, Blough BE, Rothman RB (2016) Interrogating the activity of ligands at monoamine transporters in rat brain synaptosomes. In: Bönisch S, Sitte HH (eds) Neurotransmitter transporters. Springer, New York, pp 41–52
Patel NB (2000) Mechanism of action of cathinone: the active ingredient of khat (Catha edulis). East Afr Med J 77:329–332
Peyton J, Shulgin AT (1996) Novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones. In: Organization WIP (ed) PCT. Neurobiological Technologies, Inc., Emeryville
Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147C:1–19
Rickli A, Hoener MC, Liechti ME (2015) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25:365–376
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41
Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, Baumann MH (2002) Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol 447:51–57
Rothman RB, Blough BE, Baumann MH (2008) Dopamine/serotonin releasers as medications for stimulant addictions. Prog Brain Res 172:385–406
Rudnick G, Clark J (1993) From synapse to vesicle - the reuptake and storage of biogenic-amine neurotransmitters. Biochim Biophys Acta 1144:249–263
Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M, Sandtner W, Ecker GF, Sitte HH, Baumann MH (2015) ‘Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40:1321–1331
Schindler CW, Thorndike EB, Goldberg SR, Lehner KR, Cozzi NV, Brandt SD, Baumann MH (2016) Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology 233:1981–1990
Shalabi AR, Walther D, Baumann MH, Glennon RA (2017) Deconstructed analogues of bupropion reveal structural requirements for transporter inhibition versus substrate-induced neurotransmitter release. ACS Chem Neurosci 8:1397–1403
Shekar A, Aguilar JI, Galli G, Cozzi NV, Brandt SD, Ruoho AE, Baumann MH, Matthies HJG, Galli A (2017) Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter. J Chem Neuroanat 83-84:69–74
Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470
Simmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152–160
Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433
Wee S, Woolverton WL (2004) Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend 75:271–276
Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848–854
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4